Association of polymorphisms in the promoter regions of MMP2, MMP3 and MMP9 genes with cardiovascular risk factors in patients with rheumatoid arthritis
https://doi.org/10.31549/2542-1174-2019-1-109-118
Abstract
In order to study the association of single-nucleotide polymorphisms in the promoter regions of MMP2, MMP3 and MMP9 genes with cardiovascular risk factors and carotid artery lesions in patients with rheumatoid arthritis (RA) 212 patients with RA (181 women, 31 men; mean age — 58.0 years) with moderate and high disease activity were examined (average DAS28 score — 4.96). The study established traditional and associated with the course of inflammatory arthropathy cardiovascular risk factors; genotyping was carried out with the definition of single-nucleotide polymorphisms ММР3 5A-1171 6A (rs3025058), ММР9 С-1562Т (rs3918242), ММР2 С-1306Т (rs2438650). Atherosclerotic plaques were detected by ultrasound dopplerography of brachiocephalic arteries.
In patients with the MMP9 -1562TT genotype atherosclerotic plaques were more common than in carriers of wild-type allele C (71.4 % vs. 26.3 %, p = 0.022), and this association remained even after adjustment by age and sex. The MMP2 -1306TT genotype was found in 18.6 % of patients with AB compared to 7.9 % in patients without plaque (p = 0.025), but after correction by age and sex these differences were leveled (p = 0.14).
Thus, the differences in the occurrence of different MMP2 and MMP9 genotypes depending on the presence of AB in RA patients were revealed, which indicates the possible impact of these polymorphisms on the carotid arteries damage and the formation of a predisposition to the development of cardiovascular diseases.
About the Authors
V. O. Omelchenko
Research Institute of Clinical and Experimental Lymphology
Russian Federation
Russian Federation
Omelchenko Vitaly Olegovich — Rheumatologist, Therapeutist, Junior Researcher of the Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology.
2, Timakova Str, 630117, Novosibirsk.
E. A. Letyagina
Research Institute of Clinical and Experimental Lymphology
Russian Federation
Russian Federation
Letyagina Elena Alekseevna — Cand. Sci. (Med.), Rheumatologist, Head of the Rheumatology Department, Senior Researcher of the Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology.
2, Timakova Str, 630117, Novosibirsk.
А. V. Shevchenko
Research Institute of Clinical and Experimental Lymphology
Russian Federation
Russian Federation
Shevchenko Alla Vladimirovna — Cand. Sci. (Biol.), Leading Researcher of the Laboratory of Clinical Immunogenetics, Research Institute оf Clinical and Experimental Lymphology.
2, Timakova Str, 630117, Novosibirsk.
V. I. Konenkov
Research Institute of Clinical and Experimental Lymphology
Russian Federation
Russian Federation
Konenkov Vladimir Iosifovich — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Scientific Director, Research Institute of Clinical and Experimental Lymphology.
2, Timakova Str, 630117, Novosibirsk.
T. I. Pospelova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Pospelova Tatyana Ivanovna — Dr. Sci. (Med.), Professor, Head of the Department of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University; Hematologist, Head of the City Hematology Center.
Novosibirsk.
M. A. Korolev
Research Institute of Clinical and Experimental Lymphology
Russian Federation
Russian Federation
Korolev Maksim Aleksandrovich — Cand. Sci. (Med.), Head of the Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology.
2, Timakova Str, 630117, Novosibirsk.
References
1. Mahmoudi M. et al. (2017). New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Int. J. Rheum. Dis., 20, 3, 287–297.
2. DeCoux A., Lindsey M.L., Vilarreal F., Garcia R.A., Shulz R. (2014). Myocardial matrix metalloproteinase-2: inside out and upside down. J. Mol. Cell. Cardiol., 77, 64–72.
3. Khokha R., Murthy A., Weiss A. (2013). Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat. Rev. Immunol., 13, 9, 649–665.
4. Newby A.C. (2015). Metalloproteinases promote plaque rupture and myocardial infarction: A persuasive concept waiting for clinical translation. Matrix Biol., 44–46, 157–166.
5. Price S.J., Greaves D.R., Watkins H. (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene. Role of Sp1 in allelespecific transcriptional regulation. J. Biol. Chem., 276, 10, 7549–7558.
6. Ye S. (2000). Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol., 19, 7, 623–629.
7. Bäck M., Ketelhuth D.F.J., Agewall S. (2010). Matrix metalloproteinases in atherothrombosis. Prog. Cardiovasc. Dis., 52, 5, 410–428.
8. Mazdorova E.V., Ryabikov A.N., Maksimov V.N. et al. (2010). The relationship of carotid atherosclerosis with polymorphism of the 5A/6A gene of matrix metalloproteinase-3. Bull. Sib. Branch RAMS, 30, 6, 46–51. In Russ.
9. Shevchenko V.V., Konenkov V.I., Korolev M.A., Ubshaeva Yu.B., Prokofiev V.F. (2015). Polymorphism of matrix metalloproteinases genes MMP2, MMP3, MMP9 in women with rheumatoid arthritis. Therapeutic Archive, 87, 12, 36–40.
10. Yabluchanskiy A., Ma Y., Lyer R.P., Hall M.E. (2013). Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology, 28, 6, 391–403.
Review
For citations:
Omelchenko V.O., Letyagina E.A., Shevchenko А.V., Konenkov V.I., Pospelova T.I., Korolev M.A. Association of polymorphisms in the promoter regions of MMP2, MMP3 and MMP9 genes with cardiovascular risk factors in patients with rheumatoid arthritis. Journal of Siberian Medical Sciences. 2019;(1):109-118. https://doi.org/10.31549/2542-1174-2019-1-109-118
Views:
146
Email this article 